Home   Our Business   Our Team   Therapeutic Focus   Pipeline   Partnering   Investor Relations   News & Events   Contact 
 

 

Speedel (SWX: SPPN) is a biopharmaceutical company that seeks to create value for patients, partners and investors by developing innovative therapies for cardiovascular and metabolic diseases. Speedel is a world leader in renin inhibition, a promising new approach with significant potential for treating cardiovascular diseases.

            Speedel share price SPPN CHF79.00          Speedel bond price SPP07 CHF89.70          15 May SPEEDEL ANNOUNCES FINANCIAL RESULTS FOR FIRST QUARTER 2008          21 April SPEEDEL APPOINTS NEW HEAD OF COMMUNICATIONS AND INVESTOR RELATIONS          15 April SHAREHOLDERS APPROVE ALL PROPOSALS AT ANNUAL GENERAL MEETING          01 April SPP100 (TEKTURNA/RASILEZ) REDUCES LEFT VENTRICULAR HYPERTROPHY
   Home Legal Statement Site Map Print Friendly